Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Having a heat dome, a tropical heat dome, doesn't quite ring the same either.
Too much potential to sell between now and Wednesday.
They are computing for a patient population trial size for the upcoming phase3. Whether it be 200 or 300. We shall know soon.
Thanks frrol. Really seems to fall in line.
Sunday presentation 9:30-10:30-
Dose Dependent Clinical Cognitive Improvement Observed in Mini Mental State Examination (MMSE) and Other Cognitive Markers in a Phase 2a Study in Mild-to-Moderate Alzheimer’s Patients.
Cognative improvement. I take it as meaning patients on A2-73 are regaining abilities.
Wow so you consider the 5 week data as "spectacular". I've seen good to excellent but not spectacular. Really gives credence to the 26 week data. Thanks.
Thanks KarinCA for your valued response. Yes a Prurisol sale after dose optimization would do monetary wonders. I'm also optimistic that we see great top line B-UP data possibly November. This would give validation that B platform works.
Yes thanks. I read that great study, started my basis because of it. Grant money adds value plus validation.
But why no free grant money?? You would think a Brilacidin like drug that works well and shows no bacterial resistance would be on the government approval list for money. Did Cellceutix even apply, I remember for a while there was the presidents initiative to help spring board antibiotic development.
Yes due to deadly drug resistant strains there is a great need for new antibiotics. With millions in government grants available to help meet the need my question is why in the heck is Brilacidin shelved. There was the government grant pump being made last winter and now nothing.
I believe the anecdotal evidence came from patients after around 7 months of dosing, which to me shows greater improvements were after the longer duration. Fingers crossed.
A poster can put a negative spin on positive data.
SA author quote:
Cellceutix (OTCPK:CTIX), for instance, is a company that I believe holds a high probability of success. It is a prime example of a well-positioned, small cap biotech that is working to perpetuate a promising pipeline. In the clinic, the company has demonstrated extremely encouraging trial results for three medical compounds, Prurisol, Kevetrin and Brilacidin. However, despite some truly impressive clinical data being presented, the share price has been trending unmercifully lower.
Nice write up imo.
The amazing anecdotal evidence came after around 6-8 months of therapy. So yes there sounds to be cognitive improvement over time.
Yes, PR the attendance and away we go. They must be holding for "latebreaking" other wise why not update website.
Makes perfect sense as to the delay. The thinking is that if the two poster presentations was all they would have already updated company website and PR'd titles.
you said:
[/u
My thinking is that, if there's not going to be the possibility of an oral presentation, then Anavex would have already issued a PR announcing its AAIC participation with poster presentation titles (last year's PR was issued June 30th). Therefore, because they haven't yet released a PR, it makes me believe they are about to release a PR announcing, instead, their late-breaking oral presentation. We shall see...
Due to Kevetrin's likely combination therapy it could have an even larger seat at the table.
Can't hold the presidents unemployment record against him.
I agree frrol. First very positive anecdotal evidence and now what must be positive PART B. Market cap should certainly move up on positive outcome. Looking for a PR next week that announces participation in AAIC.
Thanks Many moons...I'm holding with both hands and looking forward to great Part B. I believe longs are now in the cat bird seat.
Enter anavex in search bar. Two presentation dates will come up under list..July 24 and July 27.
https://ep70.eventpilotadmin.com/web/planner.php?id=AAIC16lite
Another Motley Fool article, Three reasons Anavex stock could rise..
http://www.fool.com/investing/2016/06/27/3-reasons-anavex-stock-could-rise.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2
I completely agree. So many lose the ability to be out on their own.
I believe the ability for one to once again go mobile is a very important sign of restored competence. This is more of a low level non-specialized activity unlike playing the piano, painting and golfing. Many older adults don't have specialized hobbies so for the masses just being able to "get around" or be aware is huge.
I think it's 4 counting the one gaining the ability to once again take mass transit.
Page 5: "Additional data, including updates on PART B, to be presented at upcoming scientific meetings".
Sounds good for AAIC.
I assume Leo scheduled soon after April 19 PR then it would probably take 30 days to actually have a meeting (last week of May). Given a 45 day response time after meeting Leo would probably get a SPA approval letter first or second week of July. Maybe..
Do we know if Leo had a meeting with the FDA regarding the proposed protocol changes toward finalizing the SPA? Scheduling a meeting was PR'd April 19. Between the first SPA proposal and the reply back for changes took around 45 days.
A real EF Hutton.
You are correct. The whole trial is a Phase 2a. Parts A and B are encompassed within.
Part A study made way for a Part B which was extended to 26 weeks. As the 26 weeks was drawing to an end, patients and caregivers messaged to continue study even longer. Another 26 weeks was added for a full 52 weeks. After the 52 weeks once again patients and caregivers petitioned to stay on medication. Once again trial was extended as a new trial to encompass 104 weeks with original 32 trial patients. This alone is well worth the ticket of admission.
Yahoo showing ask 4.82. More news out of Australia??
When patients see remission of the condition it will have been well worth it.
I agree. It seems Leo can announce trials till the cows come home but without partnership validation share price is stuck.
Fortunately this stock moves up on news either anecdotal or otherwise. Locked and loaded for next update.
This is prime PR news. Congrats to Leo and the law team.
Agree Dr Missling will present with latest trial news. AAIC is the creme de la creme (big daddy) of AZ conferences.
Small companies are constantly under the threat of shorting and mm's who prey on retail. Having more news is not better. A BP relationship would boost company to uplist plus add a revenue stream. I believe (hoping) Leo is looking into this since Prurisol results.
"miracle cure" sounds tabloid. Astounding results...that would be huuuge..
Spot on!..
"I bet this closes around 4.45
GREEN tomorrow !!!
$AVXL"